Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for HCS-2 Cells (Chondrosarcoma Cells)
- High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
- Kit includes Transfection Enhancer reagent
- Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
- Work in the presence of serum
- Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download HCS2 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for HCS2 cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 80% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems HCS-2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
HCS-2 Cell Line:
Chondrosarcoma is a form of bone cancer that affects cartilage-producing cells of the human body, representing roughly 30 percent of all skeletal system tumors. It mostly affects the axial skeleton of adults ages 20 to 60, with approximately 600 new cases diagnosed annually in the United States, according to the Atlas of Genetics and Cytogenetics in Oncology and Haematology. The HCS-2 cell line was established from human chondrosarcoma cells and is widely used in cartilage research. Medical studies for patients with certain types of sarcoma (cancer) often employ this cell line as a biological model. Altogen Biosystems provides an advanced formulation of a lipid-based HCS-2 reagent kit for chondrosarcoma cells that yields high transfection efficiency with the HCS-2 cell line, a sufficient host for biomedical research related to chondrosarcoma and cartilage. Also, the HCS-2 transfection kit is commonly employed in gene expression studies and drug discovery.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the HCS-2 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).
Figure 2. Protein expression of Cyclophilin B in HCS-2 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into HCS-2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #1761)
- 1.5 ml (Catalog #1762)
- 1.5 ml CRISPR (Catalog #2147)
- 8.0 ml (Catalog #7044)